DRUG INFO
Captopril
Drug Name:
Captopril
Indication: For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics
Pharmacology: Captopril, an angiotensin-converting enzyme (ACE) inhibitor, is used to treat hypertension, congestive heart failure, and renal syndromes such as diabetic nephropathy and scleroderma.
Mechanism Of Action: Captopril competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited.
Drug Category: Antihypertensive Agents; Angiotensin-converting Enzyme Inhibitors; ATC:C09AA01
Brand Names/Synonyms: Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Capoten; Capozide; Captolane; Captopril; Captopril [Usan:Ban:Inn:Jan]; Captoprilum [Inn-Latin]; Captopryl; Captoril; Cesplon; Dilabar; Garranil; HSDB 6527; Hipertil; Hypertil; L-Captopril; Lopirin; Lopirin [Switzerland]; Lopril; SA 333; Tenosbon; Tensobon; Tensoprel
Dosage Forms: in potencies of 12.5, 25, 50, 100mg as scored tablets
Absorption: 75% without food
Interactions:
DrugBank: Interactions for Captopril
Interactions for Captopril:
Hypotension ó Patients on Diuretic Therapy: Patients on diuretics and especially those in whom
diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may
occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the
initial dose of captopril.
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or
increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets,
USP) or initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at
least one hour after the initial dose. If hypotension occurs, the patient should be placed in a supine position and,
if necessary, receive an intravenous infusion of normal saline. This transient hypotensive response is not a
contraindication to further doses which can be given without difficulty once the blood pressure has increased after
volume expansion.
Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients
receiving captopril for heart failure are not available; therefore, nitroglycerin or other nitrates (as used for
management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting
captopril. If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower
dosage.
Agents Causing Renin Release
Captoprilís effect will be augmented by antihypertensive agents that cause renin release. For example,
diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.
Agents Affecting Sympathetic Activity
The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving
captopril alone or with diuretics. Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents
or adrenergic neuron blocking agents) should be used with caution. Beta-adrenergic blocking drugs add some further
antihypertensive effect to captopril, but the overall response is less than additive.
Agents Increasing Serum Potassium
Since captopril decreases aldosterone production, elevation of serum potassium may occur. Potassium-sparing
diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for
documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Salt
substitutes containing potassium should also be used with caution.
Inhibitors Of Endogenous Prostaglandin Synthesis
It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of
low renin hypertension. Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.
Lithium
Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving
concomitant lithium and ACE inhibitor therapy. These drugs should be coad-ministered with caution and frequent
monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of lithium
toxicity.
Cardiac Glycosides
In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction
could be found.
Loop Diuretics: Furosemide administered concurrently with cap-topril does not alter the pharmacokinetics of
captopril in renally impaired hypertensive patients.
Allopurinol
In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and
allop-urinol were administered concomitantly for 6 days.
Drug/Laboratory Test Interaction
Captopril may cause a false-positive urine test for acetone.
Chemical IUPAC Name: 1-(2-methyl-3-sulfanyl-propanoyl)pyrrolidine-2-carboxylicacid
Chemical Formula: C9H15NO3S
Half Life: < 3 hours
Drug Type: Approved Drug
# Accession No: APRD00164
CAS Registry Number: 62571-86-2